Advanced search
Start date
Betweenand

Evaluation of the potential of nanostructured lipid systems for cutaneous administration of trans-resveratrol

Abstract

The daily exposure of the skin to ultraviolet radiation can cause direct damage to DNA and cause the proliferation of reactive oxygen species (ROS), leading to a state defined as oxidative stress, which can unleash a number of skin disorders, among them skin cancer. Recent studies has shown that trans-resveratrol (RES), due to their antioxidant properties, anti-inflammatory and chemopreventive, is an potential active substance in therapy against changes resulting from oxidative stress. However, the RES has poor in vivo bioavailability due to rapid metabolism when orally administered. Thus, its cutaneous administration would be suitable to find it on their site of action. However, some of their physicochemical properties, such as limited aqueous solubility and high ability to interact with ROs, make their effectiveness on topical therapeutic more difficult since it has low penetration into the skin. The nanostructured lipid systems such as solid lipid nanoparticles (SLN) and nanostructured lipid carriers (NLC) have been successfully employed in the pharmaceutical and cosmetic area because they have the ability to compartmentalize, efficiently, several groups of active principles and modify their properties and behavior in biological environment. In this sense, SLN and NLC have been proven advantageous in cutaneous administration of various substances mainly due to its characteristics of interaction with the stratum corneum and other skin layers and capacity of drug arrangement with protective effect and sustainer of release. In this project we intend to develop and characterize, in the physical-chemical aspect, SLN and NLC for incorporating RES. Thus, it is expected to develop a delivery system for RES in nanostructural level that optimizes its use in the treatment of disorders caused by oxidative stress, especially in the treatment of melanoma. (AU)

Articles published in Agência FAPESP Newsletter about the research grant:
Articles published in other media outlets (0 total):
More itemsLess items
VEICULO: TITULO (DATA)
VEICULO: TITULO (DATA)

Scientific publications (5)
(References retrieved automatically from Web of Science and SciELO through information on FAPESP grants and their corresponding numbers as mentioned in the publications by the authors)
RIGON, ROBERTA BALANSIN; GONCALEZ, MAIRA LIMA; SEVERINO, PATRICIA; ALVES, DANILO ANTONINI; SANTANA, MARIA H. A.; SOUTO, ELIANA B.; CHORILLI, MARIUS. Solid lipid nanoparticles optimized by 2(2) factorial design for skin administration: Cytotoxicity in NIH3T3 fibroblasts. COLLOIDS AND SURFACES B-BIOINTERFACES, v. 171, p. 501-505, . (13/21500-1, 12/19568-4, 11/16888-5)
FACHINETTI, NAIARA; RIGON, ROBERTA BALANSIN; ELOY, JOSIMAR O.; SATO, MARIANA RILLO; DOS SANTOS, KAREN CRISTINA; CHORILLI, MARLUS. Comparative Study of Glyceryl Behenate or Polyoxyethylene 40 Stearate-Based Lipid Carriers for Trans-Resveratrol Delivery: Development, Characterization and Evaluation of the In Vitro Tyrosinase Inhibition. AAPS PHARMSCITECH, v. 19, n. 3, p. 1401-1409, . (13/21500-1, 11/19018-1, 12/19568-4, 11/16888-5)
DA SILVA, PATRICIA BENTO; DE FREITAS, EDUARDO SINESIO; BERNEGOSSI, JESSICA; GONCALEZ, MAIRA LIMA; SATO, MARIANA RILLO; FUJIMURA LEITE, CLARICE QUEICO; PAVAN, FERNANDO ROGERIO; CHORILLI, MARIUS. Nanotechnology-Based Drug Delivery Systems for Treatment of Tuberculosis-A Review. JOURNAL OF BIOMEDICAL NANOTECHNOLOGY, v. 12, n. 2, p. 241-260, . (13/09265-7, 12/19568-4, 13/14957-5)
RIGON, ROBERTA B.; FACHINETTI, NAIARA; SEVERINO, PATRICIA; SANTANA, MARIA H. A.; CHORILLI, MARLUS. Skin Delivery and in Vitro Biological Evaluation of Trans-Resveratrol-Loaded Solid Lipid Nanoparticles for Skin Disorder Therapies. Molecules, v. 21, n. 1, . (11/16888-5, 13/21500-1, 12/19568-4)
FONSECA-SANTOS, BRUNO; CHORILLI, MARLUS. The uses of resveratrol for neurological diseases treatment and insights for nanotechnology based-drug delivery systems. International Journal of Pharmaceutics, v. 589, . (14/24180-0, 15/05394-2, 12/19568-4)

Please report errors in scientific publications list by writing to: cdi@fapesp.br.